30 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
9
Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.
National Institute of Diabetes and Digestive and Kidney Diseases
36
Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
Bristol Myers Squibb
29
Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.
National Institute of Diabetes and Digestive and Kidney Diseases
4
Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety.
National Institute of Diabetes and Digestive and Kidney Diseases
21
The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14.
Merck Frosst Centre For Therapeutic Research
44
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists.
Merck Frosst Center For Therapeutic Research
29
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
National Institute of Diabetes and Digestive and Kidney Diseases
23
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
National Institute of Diabetes and Digestive and Kidney Diseases
1
Discovery of a series of novel 3-sulfonamido benzoic acid derivatives as promising P2Y14R antagonists for acute lung injury.
Zhengzhou University
1
Discovery of a potent and in vivo anti-inflammatory Efficacious, P2Y14R antagonist with a novel benzisoxazoles scaffold by DNA-encoded chemical library technology.
Zhengzhou University
1
Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y14 Receptor Antagonists via Structure-Guided Molecular Hybridization.
Zhengzhou University
1
Discovery of N-Substituted Acetamide Derivatives as Promising P2Y14R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay.
Children's Hospital Affiliated to Zhengzhou University
11
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
National Institute of Diabetes and Digestive and Kidney Diseases
22
Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
52
Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.
University of Nottingham
25
Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y
Soochow University
45
Bridged Piperidine Analogues of a High Affinity Naphthalene-Based P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
24
Structure-activity relationships of pyrimidine nucleotides containing a 5'-α,β-methylene diphosphonate at the P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
7
Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y
China Pharmaceutical University
36
Structure-Activity Relationship of Heterocyclic P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
36
Exploration of Alternative Scaffolds for P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
15
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.
National Institute of Diabetes and Digestive and Kidney Diseases
51
Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.
National Institute of Diabetes and Digestive and Kidney Diseases
7
Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y
China Pharmaceutical University
44
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
